MetaCap

Collegium Pharmaceutical Inc. (COLL)

NASDAQ: COLLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

24.72-0.49 (-1.94%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

COLL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$768.18M
52-week range
21.43 – 50.79
Day range
24.64 – 25.43
Volume / Avg
528.02K / 754.45K
Beta
—

52-week range

$21.43$50.79

COLL stock today

Shares of Collegium Pharmaceutical (COLL) finished lower on Nov 20 at $24.72, a drop of 1.94% or $0.49 per share, versus the S&P 500's 3.70% decline. At this level, COLL sits near the bottom of its 52-week range of $21.43 to $50.79: 51.3% below the high, set on Dec 29, 2025 and 15.4% above the low. COLL is down 46.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.2%.

Collegium Pharmaceutical trades at 22.7x its trailing twelve-month earnings per share of $1.09. Its forward P/E of 3.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Collegium Pharmaceutical

Company profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Vikram Karnani
Headquarters
Stoughton, MA
Employees
423
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Collegium Pharmaceutical generated $780.6 million in revenue, up 23.6% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $62.9 million (-9.1% year over year), for a net margin of 8.1% versus a median of 8.6% in the prior 5 years. Gross margin was 59.3% (down from 59.8%) and operating margin 23.0%.

Collegium Pharmaceutical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$780.57M$631.45M$566.77M$463.93M$276.87M
Growth+23.62%+11.41%+22.17%+67.56%-10.69%
Net income$62.87M$69.19M$48.16M$-25.00M$71.52M
EPS (diluted)$1.73$1.86$1.29$-0.74$1.86

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$44.00+77.99%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $28.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.60 vs $1.53
Surprise
-60.78%

COLL news

All COLL news

Collegium Pharmaceutical peers

Health Care sector
COLL peer companies
CompanyPrice% ChgMarket capCompare
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs COLL
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs COLL
VSTMVerastem Inc.6.33-7.73%$797.67Mvs COLL
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs COLL
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs COLL
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs COLL
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs COLL
IVAInventiva S.A. American Depository Shares3.14-8.99%$750.78Mvs COLL

Indexes, lists and sector

Collegium Pharmaceutical stock FAQ

What is Collegium Pharmaceutical's stock price today?

COLL last traded at $24.72 as of Nov 20, 4:00 PM EST, down 1.94% on the day. Prices are delayed at least 15 minutes.

What is COLL's P/E ratio?

COLL trades at a trailing P/E ratio of 22.68 and a forward P/E of 3.49.

Who is Collegium Pharmaceutical's CEO?

Mr. Vikram Karnani is the chief executive officer of Collegium Pharmaceutical Inc., which has about 423 employees.

What is the COLL 52-week high?

The 52-week high for COLL is $50.79 and the 52-week low is $21.43. The stock is currently 51.3% below its high.

Compare COLL